ClinicalTrials.gov上勃起功能障碍再生治疗试验方法学的变异性
该研究评估了ClinicalTrials.gov注册的92项勃起功能障碍再生治疗介入试验,比较体外冲击波治疗(ESWT)、富血小板血浆与干细胞注射(PRP/SC)及其他再生疗法(ORT)组的纳入排除标准与主要/次要结局。结果显示国际勃起功能指数(IIEF)评分为最常见主要结局(72%),ESWT组较PRP/SC或ORT组更常见(89% vs 44%和58%,P<.001)。结论认为各试验纳入排除标准和结局指标存在显著差异,限制了不同再生疗法的比较。
要点
- IIEF评分为最常见主要结局(72%),ESWT组(89%)高于PRP/SC组(44%)和ORT组(58%)(P<.001)。
- 安全/耐受性作为主要结局见于44%的PRP/SC试验和25%的ORT试验,ESWT试验无此主要结局(P<.001)。
- ESWT试验较PRP/SC和ORT试验更常采用性/浪漫关系相关纳入标准和癌症治疗相关排除标准。
核心结论
- 勃起功能障碍再生治疗试验的纳入/排除标准和结局指标存在显著差异,ESWT试验最常使用IIEF且纳入/排除标准最严格,提示更严谨且基于功能结局的研究;PRP/SC和ORT试验将安全/耐受性作为主要结局,可能因这些疗法的实验性质;纳入/排除标准和结局指标的差异限制了不同再生疗法的比较。
研究设计与样本
- 对ClinicalTrials.gov注册的介入性试验进行审查,检索词包括「erectile dysfunction」及「shockwave」「platelet rich plasma」「stem cell」「regenerative」「restorative」的变体,比较ESWT、PRP/SC和ORT组的纳入/排除标准及主要/次要结局,共分析92项试验。
主要发现
- 在92项试验中,IIEF评分为最常见主要结局(72%),ESWT组较PRP/SC或ORT组更常见(89% vs 44%和58%,P<.001)。
- 安全/耐受性作为主要结局见于44%的PRP/SC试验和25%的ORT试验,ESWT试验无此主要结局(P<.001)。
- ESWT试验较PRP/SC和ORT试验更常采用性/浪漫关系相关纳入标准和癌症治疗相关排除标准。
关键数值与推荐
- IIEF评分为最常见主要结局,总体占72%,ESWT组89%,PRP/SC组44%,ORT组58%(P<.001)。
- 安全/耐受性作为主要结局:PRP/SC组44%,ORT组25%,ESWT组无(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the variability in the criteria of erectile dysfunction (ED) regenerative therapy trials registered on ClinicalTrials.gov. METHODS: Interventional trials on ClinicalTrials.gov with the keywords "erectile dysfunction" and variations of "shockwave," "platelet rich plasma," "stem cell," "regenerative," and "restorative" were examined. Inclusion/exclusion criteria and primary/secondary outcomes were compared between extracorporeal shockwave therapy (ESWT), platelet rich plasma and stem cell injections (PRP/SC), and other regenerative therapies (ORT) groups. RESULTS: Of the 92 trials analyzed, International Index of Erectile Function (IIEF) score was the most common primary outcome (72%), with a higher prevalence in ESWT trials than PRP/SC or ORT trials (89% vs 44% and 58%, P <.001). Safety/tolerability was a primary outcome for 44% of PRP/SC trials and 25% of ORT trials but no ESWT trials (P <.001). ESWT trials more frequently had sexual/romantic relationship-based inclusion criteria and cancer treatment-related exclusion criteria than PRP/SC and ORT trials. CONCLUSION: There is substantial variability in the inclusion/exclusion criteria and outcome measures among ED regenerative therapy trials. ESWT trials most frequently utilized IIEF and had the strictest inclusion/exclusion criteria, suggesting more rigorous and functional outcome-based studies. Conversely, PRP/SC and ORT trials, but not ESWT trials, had safety/tolerability as a primary outcome, likely due to the experimental nature of these therapies. The variability in inclusion/exclusion criteria and outcome measures limits comparison of the various ED regenerative therapies.
引用
- Gutierrez WR, Gross MS, Ziegelmann MJ, et al. Variability in Methodology of Erectile Dysfunction Regenerative Therapy Trials on ClinicalTrials.gov. Urology. 2024. PMID: 38777189. doi:10.1016/j.urology.2024.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。